Search

Current language : English

30 SEP. 2024

LFB BIOMANUFACTURING a major player in bioproduction

News case
LFB BIOMANUFACTURING, one of the key entities in the LFB group's bioproduction activities, operates the Alès (Gard department) industrial site specialising in the manufacture of recombinant medicinal products by cell culture, and of recombinant proteins and monoclonal antibodies in particular.

LFB BIOMANUFACTURING, a major player in the production of recombinant proteins

As a CDMO, Contract Development and Manufacturing Organisation, the Alès industrial site, which is approved by the FDA, the Food and Drug Administration, provides its customers with its know-how and industrial equipment. LFB BIOMANUFACTURING offers support ranging from the development of cell lines and processes on an industrial scale to the manufacturing of clinical and commercial batches.

The Alès site in few figures:

  • + 25 yearsof experience

  • A lab technician wearing a white coat, goggles and blue gloves touches small bottles lined up in a circle.

  • Approved by the FDA

  • A laboratory technician wearing a white coat and protective goggles lifts a utensil with his orange gloves.

  • x2its bioproduction capacity

From the development of cell lines to the manufacture of recombinant medicinal products compliant with GMP standards, LFB BIOMANUFACTURING has more than 25 years of experience in monoclonal antibodies and recombinant proteins produced by cell culture.

On its FDA-approved industrial site in Alès, LFB BIOMANUFACTURING also manufactures a recombinant coagulation factor for the LFB group, as well as clinical and commercial batches on behalf of third parties.

Discover in pictures the multi-product industrial site of LFB

Combining know-how and industrial high-tech, the Alès site will be your ally in understanding and analyzing your requests, your needs and to find contractual agreements aligned with your financials.

An investment of 20 million of euros to double bioproduction capacity of the site

This project launched for the benefit of patients and to further national and European health sovereignty, for a total cost of more than 20 million euros, is fully in line with the objectives of “France 2030” and the Biotherapies / Bioproduction acceleration strategy of France’s Health Innovation 2030 plan. And it was on the premises that the planned expansion obtained financial support form the French government up to 6.7 million euros.

The expansion of the site, with the creation of around fifty jobs by 2026, is even more crucial at a time when the health industry sector is undergoing a real revolution: the arrival of medicinal products whose active substance are produced from live organisms. Today, 59% of medicinal products in development wolrdwide are biotherapies.

Alès lays the groundwork for its new capacity expansion

 

Portrait d'Herbert Guedegbe
“The new production capacities, still with single-use technologies, will allow us to offer a broader spectrum of biopharmaceutical production services to our customers, with 2,000 liters as a reference scale. This large-scale expansion in Alès, which comes on the heels of those in 2016 and 2021, reflects LFB’s strong local commitment and significant socio-economic impact in the Occitanie region of the Gard department in France, and in the Alès community in particular. This project will contribute to economic vitality at the local level, with the creation of around fifty long-term jobs by 2026.”
Herbert Guedegbe Director of the Alès industrial site and Chief Executive Officer of LFB BIOMANUFACTURING

LFB BIOMANUFACTURING joins FRANCE BioLead

The LFB announced that its subsidiary LFB BIOMANUFACTURING has become a member of the France BioLead association that supports the production of biopharmaceuticals in France. By joining France BioLead, LFB BIOMANUFACTURING has chosen to work hand in hand with a host of French players in the sector to put our country on the map of biomanufacturers of the therapeutic innovations of tomorrow.

Read the press release

These documents may be of interest to you: